Efforts paying off as eight possible coronavirus cures enter final stage

Saturday May 30 2020

This picture taken on May 23, 2020 shows a laboratory technician filling a syringe with a Covid-19 vaccine candidate ready for trial on monkeys at the National Primate Research Center of Thailand at Chulalongkorn University in Saraburi. PHOTO | MLADEN ANTONOV | AFP


There is hope for a Covid-19 vaccine with eight out of 100 worldwide projects going into clinical trial stage this week, with health experts however concerned by whether when finally approved, there will be enough for the whole world.

James Zhan, director of investment and enterprise at the United Nations Conference on Trade and Development (UNCTAD) said the eight met the required standards and will be evaluated and results announced in the next few months.

He said this in his opening remarks of a virtual meeting organised by the World Health Organisation on Wednedsay. He added demand for a Covid-19 vaccine is likely to surpass the supply hence the need to invest more in pharmaceutical development to meet the demand.

Vira celector

“Once a vaccine for Covid-19 is available, the massive demand is likely to outstrip supply quickly and if the pharmaceutical industry cannot keep up with demand, populations in poor countries will be the ones left behind,” said the director.

Pharmaceutical companies around the world have been working on developing a Covid-19 vaccine with the latest being US-based giant Merck. On Thursday, the company said it will start making two vaccines and a much-discussed experimental anti-viral compound that is in its early clinical trial.


Merck’s vaccine will focus on replicating the viral vector.

There is also a study in Wuhan, China, by Chinese drug maker, CanSino Biologics, which has been found safe and induces rapid immune response.

The findings were published last week, days after an American biotechnology company, Moderna, announced that it had also developed a vaccine that has been found to be safe and able to stimulate an immune response in the human body against the virus.

Vaccine production is currently concentrated in a few developed countries, in the hands of a few major players. According to the WHO, nearly one third (32 per cent) of vaccines have fewer than four suppliers, while nearly two thirds (63 per cent) have two or fewer prequalified products.

“Covid-19 has shown just how vulnerable medical product supply chains are when relying on a small number of manufacturers for raw materials and final products,” said WHO regulation and prequalification director Emer Cooke.

According to UNCTAD and the WHO, many developing countries need help to build their capacity to produce essential medical products, whether they are vaccines, antibiotics or personal protective equipment.

Those that have so far succeeded in establishing a local pharmaceutical industry capable of complying with international quality standards are mostly middle-income and low middle-income countries in Asia such as India and Thailand.

Lagging behind

Productive capacity has remained largely untapped in Africa, where the majority of the least developed countries are located.

Of the 40 vaccine manufacturers in 14 nations only one is African; the Biovac Institute based in Cape Town, South Africa, which currently delivers over 25 million doses of vaccines each year for illness such as measles, polio and TB.

UNCTAD cited East Africa as a region which is lagging behind in production of local pharmaceutical and together with WHO have initiated a three-year project in the region to boost production of basic antibiotics.

The $490,000 Antimicrobial Resistance (AMR) project launched a month ago to will induce investment policies, including regional medicines procurement, in the region and select countries will ensure the availability of essential antibiotics at national and regional levels.

The 2020-2013 project being implemented in Kenya, Uganda and Ethiopia is expected to boost investment incentives and public health demands for the production and supply of antimicrobials at the required quality, safety and efficacy.

EAC-based producers currently use less than 50 per cent of their capacity, due to Covid-19 related restrictions and shortages in essential active pharmaceutical ingredients.